Sequential Interferon Alpha Regimen for Cancer Stem Cell Elimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancers resistant to classical anti-proliferative chemotherapy drugs, particularly those driven by cancer stem cells, pose a challenge due to the dormancy of these cells, which makes them resistant to chemotherapy, leading to disease reoccurrence.
Innovation Solution
A sequential administration pattern involving an induction period with Interferon alpha (IFNα), followed by an IFNα-free period, and then a chemotherapy period, effectively activates quiescent hematopoietic stem cells, making them sensitive to chemotherapeutics and increasing their numbers, thereby enhancing the efficacy of chemotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If classical anti-proliferative chemotherapy drugs are used, then dividing cancer cells are eliminated, but quiescent cancer stem cells survive and cause disease reoccurrence
Solution Approach 1:
The patent applies preliminary action by administering IFNα before chemotherapy to activate quiescent cancer stem cells into the cell cycle. This pre-treatment prepares the target cells (CSCs) to become sensitive to subsequent chemotherapy, which would otherwise be resistant due to their dormant state. The sequential regimen ensures CSCs are primed for elimination before the chemotherapeutic agent is introduced.
Solution Approach 2:
The patent changes the physiological state parameter of cancer stem cells from quiescent to proliferative through IFNα treatment. By altering the cell cycle status of CSCs, they transition from a drug-resistant dormant state to a drug-sensitive active state, enabling effective chemotherapy elimination while maintaining the ability to target the root cause of relapse.
2Reliability
If IFNα is continuously administered to activate cancer stem cells, then chemotherapy sensitivity increases, but normal hematopoietic stem cells may be adversely affected
Solution Approach 1:
The patent employs periodic action through pulsed IFNα administration followed by chemotherapy, rather than continuous treatment. This intermittent regimen allows selective activation of cancer stem cells while providing windows where normal hematopoietic stem cells can recover, reducing off-target effects while maintaining therapeutic efficacy against the malignancy.
Solution Approach 2:
The treatment protocol is segmented into distinct phases: an induction period with IFNα to activate cancer stem cells, followed by a chemotherapy period to eliminate them. This segmentation separates the activation function from the elimination function, allowing selective targeting of cancer cells while minimizing impact on normal tissue through temporal and functional separation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases the sensitivity of cancer stem cells to chemotherapy, leading to their elimination and potentially preventing tumor relapse, as demonstrated by increased proliferation and survival rates in treated mice.
Implementation Method 1
IFNα has a strong, unanticipated effect on hematopoietic stem cells (HSCs) by inducing efficient activation and cell cycle entry of quiescent HSCs
Implementation Method 2
Dormant HSCs are activated to proliferate and self-renew in vivo. Pulsed IFNα treatment also increases the total number of HSCs in the organism.
Implementation Method 3
classical anti-proliferative chemotherapy drugs... elimination of dividing cells
Data Source
Figure 1Aa~1Ad
Figure 1Ba~1Bb
Figure 1C
AI summary
The present invention relates to a method of treating cancers, especially those showing resistance to classical anti-pro liferative chemotherapy drugs. Further, the invention provides a specific interferon alpha sequential regimen for treating cancers, especially those showing resistance to classical anti-proliferative chemotherapy drugs such as stem cell driven cancers. More specifically, the invention relates to a use of IFN alpha for the preparation of a pharmaceutical formulation for the treatment of cancers wherein the pharmaceutical formulation is to be administered following a sequential administration pattern i.e. an induction period wherein a therapeutically effective amount of IFN alpha is administered, a period during which ni IFN alpha is administrated and a chemotherapy period wherein a therapeutically effective amount of a chemotherapeutic agent is administered.